Goede Antistolling In Noord Nederland: Vergelijking tussen vitamine K antagonisten (VKA) en nieuwe orale anticoagulantia in patienten met boezemfibrilleren die het nu goed doen op VKAantagonisten en Nieuwe Orale anticoagulantia in patienten die momenteel goed ingesteld zijn op een vitamine K antagonist.
- Conditions
- on-valvular atrial fibrillation Vitamin K antagonists New Oral Anticoagulants
- Registration Number
- NL-OMON28322
- Lead Sponsor
- niversity Medical Centre Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 240
Inclusion Criteria
Men or women aged >= 18 years who are currently treated with VKA for non-valvular atrial fibrillation, managed by the Groningen Thrombosis Service.
-A minimum duration of 6 months of VKA treatment at the time of selection by the Thrombosis Service.
Exclusion Criteria
-A thrombo-embolic event or major bleeding ever while on VKA.
-Indication for anticoagulation other than atrial fibrillation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method et clinical benefit: composite of stroke, systemic embolism, myocardial infarction, vascular death and major bleeds. All components will also individually be assessed.
- Secondary Outcome Measures
Name Time Method - Efficacy<br /><br>- Safety<br /><br>- Burden of complications<br /><br>- Treatment expectations and satisfaction<br /><br>- Compliance<br /><br>- Quality of life<br /><br>- Feasibility